Analysts split on whether Kenvue's (KVUE) reinvestment in Neutrogena could lead to market share gains. Read more here.

Kenvue Inc. (NYSE: KVUE) is releasing its first Task Force on Climate-related Financial Disclosures (TCFD) report.

We recently compiled a list of the 10 Best Household and Personal Care Stocks to Buy. In this article, we are going to take a ...

Fintel reports that on September 24, 2024, RBC Capital downgraded their outlook for Kenvue (NYSE:KVUE) from Outperform to ...

Fintel reports that on September 24, 2024, Jefferies initiated coverage of Kenvue (NYSE:KVUE) with a Buy recommendation. ...

Previously, Kenvue and Shenzhen Nepstar have been cooperating in the over-the-counter (OTC) drug field in China for many ...

RBC Capital Markets analysts downgraded Kenvue (NYSE: KVUE) stock on Tuesday, citing challenges in the company's Skin Health & Beauty segment, particularly with its Neutrogena bra ...

On Monday, Kenvue Inc (KVUE) stock saw a modest uptick, ending the day at $23.02 which represents no change from the prior close of $23.02. The stock opened at $22.83 and touched a low of $22.76 ...

THE WHAT?  Kenvue has officially launched Aveeno® in 12 Central European markets, marking a significant milestone in the ...

First Task Force on Climate-related Financial Disclosures (TCFD) report enhances transparency and accountabilityCompany advances sustainability across ...

In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report), with ...

Kenvue, the consumer health company that markets brands such as Tylenol, Neutrogena and Listerine, has launched a global ...